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Quality of Life in Patients With Advanced Cancer: Differential
Association With Performance Status and Systemic
Inflammatory Response
Barry J.A. Laird, Marie Fallon, Marianne J. Hjermstad, Sharon Tuck, Stein Kaasa, Pa˚l Klepstad, and
Donald C. McMillan
A B S T R A C T
Purpose
Quality of life is a key component of cancer care; however, the factors that determine quality of life
are notwell understood. The aim of this studywas to examine the relationship between quality of life
parameters, performance status (PS), and the systemic inflammatory response in patients with
advanced cancer.
Methods
An international biobank of patients with advanced cancer was analyzed. Quality of life was
assessed at a single time point by using the European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire C-30 (EORTCQLQ-C30). PSwas assessed by using the Eastern
Cooperative Oncology Group (ECOG) classification. Systemic inflammation was assessed by using
the modified Glasgow Prognostic Score (mGPS), which combines C-reactive protein and albumin.
The relationship between quality of life parameters, ECOG PS, and the mGPS was examined.
Results
Data were available for 2,520 patients, and the most common cancers were GI (585 patients
[22.2%]) and pulmonary (443 patients [17.6%]). The median survival was 4.25 months (interquartile
range, 1.36 to 12.9 months). Increasing mGPS (systemic inflammation) and deteriorating PS were
associated with deterioration in quality-of-life parameters (P , .001). Increasing systemic inflammation
was associated with deterioration in quality-of-life parameters independent of PS.
Conclusion
Systemic inflammation was associated with quality-of-life parameters independent of PS in patients
with advanced cancer. Further investigation of these relationships in longitudinal studies and in-
vestigations of possible effects of attenuating systemic inflammation are now warranted.
J Clin Oncol 34:2769-2775. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Clinical trials in oncology have changed in the
past 30 years. The initial evaluation criteria for
clinical trials focused on tumor size, time to
progression, and survival. However, over the past
three decades, there has been an evolution toward
the inclusion of quality-of-life parameters, and
these are now recognized as a key component in
clinical trial evaluations.1,2 Indeed, the vast ma-
jority of clinical trials now report quality-of-life
parameters as either primary or secondary end
points, and trials that improve quality of life in
patients with cancer are of increasing interest,
particularly in patients with advanced cancer in
whom the scope for improving survival has
proved to be limited.
One of the most common instruments used
to assess quality of life is the European Organi-
sation for the Research and Treatment of Can-
cer Quality of Life Questionnaire C30 (EORTC
QLQ-C30),3 which has been used in more than
9,000 clinical trials.2 The EORTC QLQ-C30
assesses various patient-reported outcomes, in-
cluding level of functioning, overall or global
quality of life, and symptoms such as pain
and depression.
Physical functioning is clearly a key com-
ponent of quality of life and is usually assessed
objectively by using performance status (PS)
scales.4,5 Moreover, because of its clear prognostic
© 2016 by American Society of Clinical Oncology 2769
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value for survival, PS is used to guide the clinician regarding the
most appropriate treatment for patients with advanced cancer. As
early as the first century, Celsus’DeMedicina described the cardinal
signs of inflammation as a key component of pain and disease.6
These early observations are now supported by recent consistent
evidence that pain and other symptoms are related to systemic
inflammation in the cancer setting.7,8
The presence of systemic inflammation is also recognized
to have independent prognostic value in patients with cancer.
In particular, the combination of C-reactive protein (CRP)
and albumin (termed the modified Glasgow Prognostic Score
[mGPS]) has been shown to have prognostic value comple-
mentary to PS in patients with advanced cancer.9-12 In patients
near the end of life, both PS and the systemic inflammatory
response are affected, and therefore deteriorating quality of life
may be affected by decreasing PS, systemic inflammation, or
both. The question is: How do PS and the systemic inflammatory
response interact with patient-reported outcome measures
(PROMs) of quality of life? If these PROMs were shown to be
associated specifically with PS and/or systemic inflammation,
then this would provide valuable insight into their etiology.
Furthermore, it would enable key components of quality of life to
be targeted by using interventions that improve PS and/or at-
tenuate systemic inflammation.
The aim of this study was therefore to evaluate key compo-
nents of quality of life (by using PROMs) and to examine their
relationship to PS and the systemic inflammatory response. The
hypothesis being examined was that systemic inflammation is
associated with quality of life independent of PS.
METHODS
Study Sample
An international biobank of adult patients with cancer was an-
alyzed. These data were collected prospectively at a single time point
from multiple centers across Europe.13,14 Patients were age 18 years or
older, had metastatic or locoregional cancer, and were recruited from
both inpatient and outpatient settings by using a convenience sampling
approach. Patients who could not communicate in the primary lan-
guage at the study center and/or had a psychiatric diagnosis with
cognitive impairment were excluded. All patients provided written
informed consent for their data to be stored and assessed, with ethical
approval accordingly.
Procedure and Assessment
All patients had age, sex, primary cancer type, presence of metastatic
disease, and PS recorded. Data were collected on quality-of-life variables by
using PROMs from the EORTC QLQ-C30 version 3.3 The following were
assessed: global health status, role function, cognitive function, physical
function, emotional function, social function, fatigue, nausea and vom-
iting, pain, dyspnea, insomnia, appetite, constipation, and diarrhea.
Systemic inflammation was measured by using CRP and albumin and
was taken by venous blood sampling at point of consent. The limit of
detection of CRP was, 5 mg/L, and all samples (CRP and albumin) were
analyzed at a central laboratory. The mGPS was calculated as follows:
• CRP # 10 mg/L = 0
• CRP . 10 mg/L = 1
• CRP . 10 mg/L and albumin , 35 g/L = 2
Increasing mGPS score is related to increasing systemic inflammation,
and these cutoffs are based on previous studies that examined the mGPS.9
Statistical Analysis
Key patient demographic characteristics were described. If a variable was
considered binary and/or categorical, then the number and percentage across
the patient population are presented. The normality of the data of the EORTC-
QLQ-C30 scales was examined by using Q-Q plots (Data Supplement). The
plots indicated that it was reasonable to present parametric statistics.
If a variable was considered continuous, then the mean and standard
deviation are presented (unless otherwise specified). All statistical testing
was conducted at the 5% significance level and 95% CIs are reported
throughout. Because of the large number of comparisons depicted in
Tables 1 and 2, the Bonferroni correction was applied, and statistical
significance was taken as P , .001.
Assessment of PROMs was performed by using the EORTC QLQ-C30
scales calculated by the scoring procedures as described by Aaronson
et al.3,15 EORTC QLQ-C30 scales were analyzed as discrete categories
representing underlying continuous constructs. A high score on a global
health or functional scale represents a high or healthy level of functioning;
a high score on the symptom scale represents a high level of symptoms.
Differences in EORTC scales were interpreted as having little, moderate,
or substantial effect clinically, on the basis of a change of . 5 to 10, 10 to
20, or . 20 points, respectively.16,17 To facilitate analysis, Karnofsky PS
was transformed as described by Ma et al18 into Eastern Cooperative
Oncology Group (ECOG) PS groupings. The mGPSs were grouped by
using thresholds described previously.
To examine the relationship between PROMs and ECOG PS, a series of
x2 tests for trend were used. Similar analysis was performed to examine the
relationship between PROMs and mGPS. A multivariate logistic regression
analysis was also performed by using selected functional and symptom scales
separately to help predict mGPS in the ECOG PS 0-1 cohort.
To examine whether any of the statistically significant EORTC QLQ-
C30 parameters were individually associated with mGPS in the ECOG PS 0-1
cohort, multivariate logistic regression analysis was carried out for functional
and symptom scales separately. Backward elimination regression was per-
formed in which the significance level to stay in the model was set at 0.1. All
analyses were performed in SPSS Version 21.0 (SPSS, Chicago, IL).
RESULTS
Of the complete biobank data (N = 3,311), data on systemic in-
flammation and PSwere available for 2,520 patients. EORTCQLQ-
C30 data were available for approximately 2,200 patients. Patient
demographic characteristics are provided in Table 3. The most
common cancer types were GI (585 patients [23.2%]) and pul-
monary (443 patients [17.6%]). The mean age was 62.4 years
(standard deviation, 12.21 years), and the median survival was
4.25 months (interquartile range, 1.36 to 12.9 months). The
majority of patients were inpatients (1,947 [77.3%]), and the
median PS was 2 (interquartile range, 1 to 3). In all, 1,830 patients
(72.6%) had metastatic disease.
The relationship between PROMs (global health, role func-
tion, cognitive function, physical function, emotional function,
and social function), PS, and systemic inflammation is depicted in
Table 1. Deteriorating PS and increasing mGPS (systemic in-
flammation) were individually associated with a worsening in all
EORTC PROMs (P , .001 and P , .001, respectively, for all
PROMs). In particular, there was a deterioration in global health
outcomes across mGPSs independent of PS (ie, PS 0-1 category:
mGPS 0, 56.3; mGPS 1, 51.1; mGPS 2, 45.3; P , .001). A similar
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pattern was also seen with role, physical, and social outcome
measures (P , .001).
Because it was anticipated that patient-assessed physical
function (EORTC) and clinician-assessed PS (ECOG) both
reflect activity level, the relationship between them was ex-
amined and is shown in Figure 1. The Spearman rank corre-
lation was –0.61 (P , .001). This shows that as PS deteriorated
(ie, increasing ECOG score), patient-assessed physical function
score decreased.
The relationship between symptom components of quality of
life (fatigue, nausea, pain, dyspnea, sleep, appetite, constipation,
and diarrhea), PS, and systemic inflammation is depicted in
Table 2. Deteriorating PS and increasing mGPS (systemic in-
flammation) were individually associated with a worsening of
almost all symptoms: fatigue (P, .001 and P, .001, respectively),
nausea (P , .001 and P , .001, respectively), pain (P , .001 and
P , .001, respectively), dyspnea (P , .001 and P , .001, re-
spectively), and appetite (P , .001 and P , .001, respectively).
However, a worsening in constipation symptoms was associated
with deteriorating PS only (P , .001). In particular, there was
a deterioration in fatigue across mGPS categories, despite having
good PS (ie, PS 0-1 category: mGPS 0, 44.5; mGPS 1, 51.6; mGPS 2,
57.2; P, .001). A similar pattern was also seen with pain, appetite,
and diarrhea (P , .001).
Table 1. Relationship Between EORTC QLQ-C30 Global Health Status/Functional Scales (discrete categories) and ECOG PS and mGPS
ECOG PS
mGPS
0 1 2 All
PTotal No. Mean SD Total No. Mean SD Total No. Mean SD Total No. Mean SD
Global health
0-1 313 56.3 23.7 148 51.1 23.1 197 45.3 21.6 658 51.8 23.4 , .001
2 295 44.9 23.6 211 40.4 20.3 398 37.2 23.2 904 40.5 22.9 , .001
3 119 40.1 24.4 65 33.2 21.5 326 34.8 23.5 510 35.8 23.6 .062
4 26 31.4 25.4 6 30.6 16.4 80 31.5 24.4 112 31.4 24.1 .983
All 753 48.4 24.9 430 42.9 22.4 1,010 37.6 23.5 2,184 42.3 24.2 , .001
P , .001 , .001 , .001 , .001
Role
0-1 315 56.5 32.7 148 47.0 31.0 198 38.4 32.1 661 48.9 33.0 , .001
2 297 32.1 30.4 211 30.4 27.6 398 24.7 28.0 906 28.5 28.9 .001
3 120 19.7 26.0 69 15.9 25.3 333 15.3 23.6 522 16.4 24.4 .099
4 27 7.4 16.2 6 8.3 20.4 80 8.1 15.9 113 8.0 16.1 .848
All 759 39.3 34.0 434 33.4 30.4 1,009 23.0 28.3 2,202 30.7 31.7 , .001
P , .001 , .001 , .001 , .001
Cognitive
0-1 314 78.9 22.9 149 78.2 22.7 199 74.6 24.0 662 77.4 23.2 .050
2 296 69.3 25.5 212 70.9 23.7 400 64.6 27.1 908 67.6 25.9 .013
3 119 61.6 27.0 68 63.2 28.0 332 58.7 28.1 519 60.0 27.8 .242
4 26 61.5 27.8 6 72.2 25.1 80 49.4 28.0 112 53.4 28.4 .035
All 755 71.8 25.6 435 72.2 24.5 1,011 63.4 27.8 2,201 68.0 26.7 , .001
P , .001 , .001 , .001 , .001
Physical
0-1 315 69.2 20.3 149 63.7 23.1 205 58.7 24.0 663 64.8 22.5 , .001
2 298 48.7 22.5 216 46.1 20.1 439 43.2 21.5 914 45.7 21.6 .001
3 119 24.0 21.4 69 26.3 24.0 415 22.5 19.8 520 23.3 20.8 .345
4 27 9.4 17.2 6 14.4 32.2 153 13.2 16.8 113 12.4 17.8 .353
All 759 51.9 27.6 440 48.5 25.6 1,212 37.0 25.8 2,210 44.5 27.3 , .001
P , .001 , .001 , .001 , .001
Emotional
0-1 314 73.4 23.4 149 72.1 22.8 199 69.6 24.0 662 71.9 23.5 .080
2 296 67.9 23.9 212 71.0 20.9 400 66.5 26.4 908 68.0 24.5 .371
3 119 68.3 26.4 67 60.2 24.4 332 64.9 26.7 518 65.1 26.4 .374
4 26 66.8 23.8 6 66.7 24.2 80 59.1 25.9 112 61.3 25.4 .160
All 755 70.2 24.3 434 69.7 22.5 1,011 65.9 26.1 2,200 68.2 24.9 , .001
P .011 .002 .003 , .001
Social
0-1 314 65.5 29.9 149 57.6 30.4 198 50.5 32.6 661 59.3 31.5 , .001
2 296 46.6 31.3 211 49.8 30.2 400 41.0 31.7 907 44.9 31.4 .012
3 119 49.0 35.7 67 43.3 35.8 330 40.2 32.7 516 42.6 33.9 .016
4 26 44.9 35.5 6 19.4 22.2 80 38.7 32.0 112 39.1 32.6 .537
All 755 54.8 32.9 433 51.0 31.6 1,008 42.4 32.4 2,196 48.3 32.9 , .001
P , .001 , .001 .001 , .001
NOTE. The columns of P values show the x2 test for trend results examining the relationship betweenmodified Glasgow Prognostic Score (mGPS) and the global health/
patient-reported outcomemeasures (PROMs) discrete categories for each performance status group separately. The rows of P values show the x2 test for trend results
examining the relationship between performance status and global health/PROMs discrete categories for each mGPS group separately.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire C-30; SD, standard deviation.
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Table 2. Relationship Between EORTC QLQ-C30 Symptom Scales (discrete categories) and ECOG PS and mGPS
ECOG PS
mGPS
0 1 2 All
PTotal No. Mean SD Total No. Mean SD Total No. Mean SD Total No. Mean SD
Fatigue
0-1 315 44.5 25.8 149 51.6 24.0 199 57.2 25.8 663 49.9 25.9 , .001
2 296 59.3 23.7 212 62.7 23.5 401 68.7 24.4 909 64.2 24.3 , .001
3 120 65.2 24.7 68 70.3 23.2 333 68.2 24.4 521 67.8 24.3 .330
4 26 68.4 23.5 6 74.1 25.0 80 71.7 22.2 112 71.0 22.5 .551
All 757 54.4 26.2 435 60.2 24.5 1,013 66.5 24.9 2,205 61.1 25.8 , .001
P , .001 , .001 , .001 , .001
Nausea
0-1 314 15.5 23.1 149 14.5 20.4 199 20.9 24.6 662 16.9 23.1 .017
2 297 22.2 27.2 215 21.4 24.5 401 29.5 31.3 913 25.2 28.7 , .001
3 120 18.3 25.0 68 27.0 29.4 334 23.3 27.0 522 22.6 26.9 .152
4 26 17.9 24.0 6 33.3 36.5 81 24.5 29.8 113 23.5 28.9 .381
All 757 18.6 25.2 438 20.1 24.5 1,015 25.4 28.7 2,210 22.0 26.9 , .001
P .109 , .001 .935 , .001
Pain
0-1 315 37.1 30.3 149 51.1 31.2 199 52.0 32.2 663 44.7 31.9 , .001
2 297 54.1 30.5 215 60.1 28.2 401 61.5 30.5 913 58.8 30.1 .002
3 120 56.5 31.3 69 68.8 26.8 333 62.9 28.3 522 62.2 29.0 .100
4 26 55.8 35.9 6 77.8 32.8 81 65.4 27.7 113 63.9 30.2 .212
All 758 47.5 31.9 439 58.7 29.7 1,014 60.4 30.2 2,211 55.6 31.2 , .001
P , .001 , .001 , .001 , .001
Dyspnea
0-1 314 23.0 27.6 149 27.7 30.9 199 28.5 32.4 662 25.7 29.9 .036
2 295 28.7 32.3 215 33.2 34.2 400 37.8 35.6 910 33.7 34.4 .001
3 119 34.5 33.0 69 41.5 36.8 331 37.5 34.2 519 37.3 34.3 .552
4 26 30.8 31.2 6 44.4 45.5 81 45.7 39.2 113 42.2 38.1 .089
All 754 27.3 30.7 439 32.8 33.9 1,011 36.5 35.1 2,204 32.6 33.6 , .001
P .001 .004 , .001 , .001
Sleep
0-1 315 28.8 30.7 149 31.1 32.0 199 34.5 33.7 663 31.0 31.6 .046
2 296 36.5 33.1 214 35.8 33.8 401 36.7 34.7 911 36.4 34.0 .931
3 120 35.6 34.5 66 34.8 32.3 331 31.7 33.0 517 33.0 33.2 .249
4 26 30.8 35.2 6 16.7 27.9 81 28.8 33.2 113 28.6 33.3 .892
All 757 32.9 32.6 435 33.8 32.3 1,012 34.0 33.9 2,204 33.6 33.1 .514
P .041 .585 .072 .834
Appetite
0-1 314 28.7 31.9 149 32.9 34.2 199 47.4 35.3 662 35.2 34.4 , .001
2 297 39.8 36.9 213 44.0 35.8 398 55.9 37.4 908 47.9 37.5 , .001
3 120 36.1 34.7 68 56.4 34.7 333 54.3 36.5 521 50.4 36.6 , .001
4 26 43.6 36.2 6 44.4 45.5 81 55.6 36.1 113 52.2 36.7 .132
All 757 34.7 34.9 436 42.1 36.0 1,011 53.7 36.7 2,204 44.9 36.9 , .001
P .001 , .001 .086 , .001
Constipation
0-1 313 29.1 33.8 149 35.6 34.1 199 36.3 36.0 661 32.7 34.7 .015
2 297 41.2 37.3 213 42.7 35.8 400 46.3 39.2 910 43.8 37.9 .071
3 118 46.3 36.7 68 56.9 36.0 329 41.9 37.5 515 44.9 37.4 .107
4 26 53.8 41.2 6 38.9 49.1 79 44.7 38.8 111 46.5 39.8 .347
All 754 37.4 36.7 436 42.4 36.0 1,007 42.8 38.1 2,197 40.9 37.3 .003
P , .001 , .001 .214 , .001
Diarrhea
0-1 314 16.7 26.5 149 13.2 23.5 199 26.3 33.3 662 18.8 28.5 .001
2 297 19.5 31.2 212 16.7 28.0 398 22.2 30.7 907 20.0 30.3 .203
3 117 17.1 28.6 67 13.4 27.3 329 20.6 33.3 513 18.8 31.6 .197
4 26 14.1 23.4 6 5.6 13.6 80 16.3 27.6 112 15.2 26.0 .625
All 754 17.8 28.7 434 14.8 26.3 1,006 22.0 31.9 2,194 19.1 29.9 .002
P .905 .925 .011 .506
NOTE. The columns of P values show the x2 test for trend results examining the relationship betweenmodifiedGlasgow Prognostic Score (mGPS) and the global health/
patient-reported outcomemeasures (PROMs) discrete categories for each performance status group separately. The rows of P values show the x2 test for trend results
examining the relationship between performance status and global health/PROMs discrete categories for each mGPS group separately.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire C-30; SD, standard deviation.
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Of the significant function scales (ie, role function, physical
function, and social function) on mGPS, only role function was
independently associated with the mGPS (odds ratio [OR], 0.986;
95% CI, 0.980 to 0.991; P , .001). Of the significant symptom
scales (ie, fatigue, pain, and appetite) on mGPS, only fatigue (OR,
1.009; 95% CI, 1.002 to 1.017; P = .018) and appetite (OR, 1.012;
95% CI, 1.006 to 1.017; P , .001) were independently associated
with the mGPS.
Of those independently associated (eg, in ECOG PS 0-1
category) with mGPS, role function, fatigue, and appetite had
differences of 18.1 points (32.0%), 12.7 points (22.2%), and 18.7
points (39.4%) across mGPS categories, consistent with clinically
meaningful deterioration in quality of life.
DISCUSSION
To the best of our knowledge, this is the first study to examine
how the combination of PS (ECOG) and systemic inflammation
(mGPS) relates to functional and symptom scales of quality of life
in patients with advanced cancer. In particular, the results of this
study show a clear and consistent relationship between worsening
of quality-of-life parameters, such as global health, role, physical
and social functioning, and fatigue, pain, appetite symptoms with
increased systemic inflammation, independent of good PS. Taken
together, the results of this large cohort study suggest that the
presence of a systemic inflammatory response is associated with
functional decline and may be a factor associated with the de-
terioration of quality of life in patients with advanced cancer.
The implications of these results are several and profound.
First, given that the same combination of ECOG PS and the mGPS
has previously been shown to effectively predict survival rates in
patients with advanced cancer,10 this objectively ties the deterioration
of different PROMs to the deterioration of likely survival. Therefore,
for the first time, the combination of ECOG PS and mGPS provides
a simple framework for the study of quality of life and the impact of
symptom control on survival in patients with advanced cancer.
Second, the findings support the rationale that attenuation of
the systemic inflammatory response may improve quality of life
in patients with cancer.19 The systemic inflammatory response in
patients with cancer primarily reflects an upregulation of the innate
immune/inflammatory response. Whether this results primarily
from proinflammatory cytokines from tumor cells, stromal cells,
inflammatory cells, or a combination is not yet clear. Given these
results and their role in elaborating the systemic inflammatory re-
sponse and changes in tissue metabolism, the interleukin-6 (IL-6)/
Janus kinase/signal transducer and activator of transcription (JAK/
STAT) pathway is a plausible mediator of the deterioration of PS and
quality of life in patients with advanced cancer.20,21 This approach is
the subject of ongoing clinical trials and will provide new insight into
whether the relationship between the systemic inflammatory re-
sponse and quality of life is causal in nature.20 Indeed, it is our hope
that our results will stimulate further studies to examine the nature
of the relationship between the components of the EORTC QLQ-
C30, ECOG PS, and the mGPS in clinical trial data.
These persuasive arguments challenge the traditional paradigm
in advanced cancer of treating symptoms once they have developed.
This is in contrast to other disease groups (eg, cardiovascular disease,
diabetes, and rheumatology) in which treatment is aimed at prevention
Table 3. Patient Demographic Characteristics (N = 2,520)
Characteristic No. %
Age, years
, 65 1,382 54.8
65-74 704 27.9
$ 75 434 17.2
Sex
Male 1,304 51.7
Female 1,216 48.3
Primary cancer site
Breast 341 13.5
Urologic 423 16.8
Gynecologic 154 6.1
GI 585 23.2
Hematologic 133 5.3
Head and neck 106 4.2
Pulmonary 443 17.6
Other 335 13.3
Spread
None 302 12.0
Locoregional 388 15.4
Metastases 1,830 72.6
Place of care
Inpatient 1,947 77.3
Outpatient 573 22.8
ECOG performance score
0-1 682 27.1
2 994 39.4
3 646 25.6
4 198 7.9
mGPS
0 807 32.0
1 501 19.9
2 1,212 48.1
Abbreviations: ECOG, Eastern Cooperative Oncology Group; mGPS, modified
Glasgow Prognostic Score.
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Fig 1. Box and whisker plot showing the relationship between European Organi-
sation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire
C-30 physical function scale and Eastern Cooperative Oncology Group performance
status (ECOGPS). Spearman rank correlationwas20.61 (P, .001). (*) Outlier values
that are greater than 1.5 3 interquartile range.
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or risk reduction of disease sequelae.22,23 Because there is an attitude of
therapeutic nihilism that refractory cancer symptoms (eg, difficult-to-
control pain, fatigue, and cachexia) are an inevitable consequence of
advanced disease, there has been a failure to advance the research agenda
in symptommanagement.Now there is a sound rationale for a proactive
or preventative approach to treating symptoms in advanced cancer and
the systemic inflammatory response is a feasible target for this.
Emerging evidence seems to support this rationale. To illustrate,
the beneficial effects on cancer cachexia in non–small-cell lung cancer
have been reported by using tocilizumab (an IL-6 receptor antibody),
IL-6 having a seminal role in tumorigenesis.24 Further downstream in
the innate immunity pathway, JAK1 inhibition by using ruxolitinib
improved symptoms in patients with myelofibrosis.25 Future clinical
trials that target inflammation through both specific and broad
immunomodulatory approaches and that have quality-of-life pa-
rameters as primary end points are now warranted.
In patients near the end of life, both PS and the systemic in-
flammatory response are altered, and therefore poorer quality of life
may be a result of poorer PS, systemic inflammation, or both. A
possible alternative explanation is that systemic inflammation merely
reflects the tumor burden and that it is the tumor-specific molecular
processes that drive both the alterations in PS and the systemic in-
flammatory response. However, over the last 15 years, there has been
an evolution in the thinking of how tumors grow and disseminate:
from the earlier work in which the intrinsic characteristics of the
tumor were considered to largely determined the process26 to an
understanding that local27 and systemic inflammatory responses28 play
a key role in disease progression and survival in patients with cancer.
This concept is consistent with recent progress in the area of
immuno-oncology and suggests a more complex tumor-host in-
teraction. The systemic inflammatory response is now recognized
to have prognostic value, independent of tumor stage, in patients
with cancer.9 In particular, the combination of CRP and albumin to
form a cumulative systemic inflammation–based prognostic score
(mGPS) has been shown to have prognostic value complementary
to PS in patients with advanced cancer in whom tumor stage has
less value.9-12 That the systemic inflammatory response is asso-
ciated with a poorer quality of life, even in patients with good PS,
suggests an inflammatory basis, at least in part, to changes in quality
of life and PROMs in patients with advanced cancer. Furthermore, it
suggests that immune interventions that attenuate systemic inflam-
mation may improve key components of quality of life.
The main limitation of this study is that other factors (eg,
oncology treatment) may have affected the quality-of-life parameters
reported. However, the size of the population studied combined with
the heterogeneity of the primary cancer types suggest that they would
have been unlikely to affect the quality-of-life parameters. In addition,
the convenience sampling approach in the primary data collection
resulted in small numbers of patients with ECOG PS 4 category, but
this may reflect that such patients are too unwell to participate in
clinical trials. In this study, the associations reported cannot be
interpreted as having causal relationship.
Another interesting aspect is whether patient-assessed mea-
sures are comparable to physician-assessed measures: EORTC
QLQ-C30 Physical Function versus ECOG PS. In this study, there
was a strong negative correlation (rs = –0.61; P , .001) between the
patient-assessed physical function (EORTC) and clinician-assessed
PS (ECOG), that is, as physical function score decreases (worsens) PS
increases (gets worse).29 This seems to confirm that the patient and
physician are both assessing a similar quality-of-life domain.
Several function scales (role function, physical function, and
social function) were associated with the mGPS independent of
good ECOG PS. However, on multiple regression analysis, only role
function was independently associated with the mGPS. Similarly,
several symptom scales (fatigue, pain, and appetite) were associated
with the mGPS independent of ECOG PS. However, on multiple
regression analysis, only fatigue and appetite symptoms were in-
dependently associated with the mGPS. Taken together, our results
suggest that the systemic inflammatory response plays a role in the
deterioration of quality of life in patients with advanced cancer. In
addition, the findings suggest that, independent of good PS, the sys-
temic inflammatory response has its main effect on appetite, fatigue,
and role functioning of patients with advanced cancer. Further lon-
gitudinal and interventional studies are required to tease out the
nature of these independent relationships.
In conclusion, the results of this study in a large international
cohort highlight the relationship between systemic inflammatory
response and deterioration of quality of life, independent of PS,
in patients with advanced cancer. These results have significant
implications for better understanding and improving treatment of
the deterioration of quality of life commonly experienced in pa-
tients with advanced cancer. The increasing implementation of
immunotherapies in the treatment of advanced cancer provide
a fertile ground for expanding the role of these therapies in im-
proving patients’ quality of life. After all, in patients with advanced
cancer, optimizing quality of life is the central tenet of cancer care.
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